Daily Maverick on MSN38m
US funding cuts imperil African search for HIV vaccineA groundbreaking project to study potential HIV vaccines in several African countries has been derailed by an abrupt cut in ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people living with HIV and outlines future research priorities.
The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 ...
Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...
A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...
11h
UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...
COVID-19 took the lives of more than one million Americans and nearly 116,000 Californians, according to the Centers for Disease Control and Prevention.
Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...
An effective HIV-1 vaccine must therefore elicit antibodies that can neutralize many variants of the virus. While broadly neutralizing antibodies (bnAbs) have been isolated from HIV-1 infected ...
A new study published in The Lancet HIV reveals gaps in knowledge surrounding the prevention of HPV-related cancers in people ...
The COVID-19 pandemic transformed over the past five years from a catastrophic threat that has killed over 7 million people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback